Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Niagen Bioscience, Inc. (NASDAQ:NAGE) has been given an average rating of “Moderate Buy” by the six ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $13.42.

A number of research firms have recently issued reports on NAGE. Roth Capital restated a “buy” rating and issued a $23.00 target price (up previously from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th. Wall Street Zen lowered Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. Canaccord Genuity Group increased their target price on Niagen Bioscience from $13.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, June 10th. HC Wainwright increased their target price on Niagen Bioscience from $11.00 to $12.00 and gave the company a “buy” rating in a report on Monday, August 11th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a report on Saturday, September 27th.

Niagen Bioscience Stock Down 6.1%

NAGE opened at $6.93 on Friday. The firm has a market cap of $552.67 million, a PE ratio of 33.00 and a beta of 2.13. The business has a fifty day simple moving average of $9.57 and a 200-day simple moving average of $9.48. Niagen Bioscience has a fifty-two week low of $3.18 and a fifty-two week high of $14.69.

Niagen Bioscience (NASDAQ:NAGE) last released its earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. The company had revenue of $31.12 million during the quarter, compared to analyst estimates of $28.55 million. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.

Institutional Trading of Niagen Bioscience

A number of institutional investors have recently bought and sold shares of NAGE. State of Wyoming acquired a new stake in Niagen Bioscience during the fourth quarter valued at $39,000. ProShare Advisors LLC acquired a new stake in Niagen Bioscience during the fourth quarter valued at $74,000. Deutsche Bank AG boosted its position in Niagen Bioscience by 1,733.4% during the fourth quarter. Deutsche Bank AG now owns 26,878 shares of the company’s stock valued at $143,000 after purchasing an additional 25,412 shares during the last quarter. Bank of America Corp DE boosted its position in Niagen Bioscience by 89.5% during the fourth quarter. Bank of America Corp DE now owns 52,144 shares of the company’s stock valued at $277,000 after purchasing an additional 24,622 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Niagen Bioscience during the fourth quarter valued at $555,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.